ID   KP-MRT-KS
AC   CVCL_A2FN
SY   Kyoto Pediatrics-Malignant Rhabdoid Tumor-KS
DR   cancercelllines; CVCL_A2FN
DR   Wikidata; Q105509812
RX   PubMed=33109553;
CC   Population: Japanese.
CC   Doubling time: ~48 hours (PubMed=33109553).
CC   Karyotypic information: Has a hypo-tetraploid karyotype (PubMed=33109553).
CC   Sequence variation: Mutation; HGNC; HGNC:11103; SMARCB1; Simple; p.Arg53Ter (c.157C>T); ClinVar=VCV000944246; Zygosity=Heterozygous (PubMed=33109553).
CC   Sequence variation: Mutation; HGNC; HGNC:11103; SMARCB1; Simple; p.Arg190Profs*27 (c.551_569dup19); Zygosity=Heterozygous (PubMed=33109553).
CC   Omics: DNA methylation analysis.
CC   Derived from site: In situ; Neck; UBERON=UBERON_0000974.
DI   NCIt; C6586; Extrarenal rhabdoid tumor
DI   ORDO; Orphanet_69077; Rhabdoid tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A2FP ! KP-MRT-KSa
SX   Female
AG   7M
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 19-12-24; Version: 7
//
RX   PubMed=33109553; DOI=10.21873/anticanres.14636;
RA   Kuwahara Y., Iehara T., Ichise E., Katsumi Y., Ouchi K., Tsuchiya K.,
RA   Miyachi M., Konishi E., Sasajima H., Nakamura S., Fumino S.,
RA   Tajiri T., Johann P.D., Fruhwald M.C., Yoshida T., Okuda T.,
RA   Hosoi H.;
RT   "Novel two MRT cell lines established from multiple sites of a
RT   synchronous MRT patient.";
RL   Anticancer Res. 40:6159-6170(2020).
//